title: CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
abstract: Neuroblastoma (NB), the most frequent extracranial solid tumor of children accounting for nearly 15% of all childhood cancer mortality, displays overexpression of antiapoptotic Bcl-2 and Mcl-1 in aggressive forms of the disease. The clinical phase 2 drug roscovitine (CYC202, seliciclib), a relatively selective inhibitor of cyclin-dependent kinases (CDKs), and CR8, a recently developed and more potent analog, induce concentration-dependent apoptotic cell death of NB cells (average IC(50) values: 24.2 µM and 0.4 µM for roscovitine and CR8, respectively). Both roscovitine and CR8 trigger rapid down-regulation of the short-lived survival factor Mcl-1 in the 9 investigated human NB cell lines. This effect was further analyzed in the human SH-SY5Y NB cell line. Down-regulation of Mcl-1 appears to depend on inhibition of CDKs rather than on interaction of roscovitine and CR8 with their secondary targets. CR8 is an adenosine triphosphate-competitive inhibitor of CDK9, and the structure of a CDK9/cyclin T/CR8 complex is described. Mcl-1 down-regulation occurs both at the mRNA and protein levels. This effect can be accounted for by a reduction in Mcl-1 protein synthesis, under stable Mcl-1 degradation conditions. Mcl-1 down-regulation is accompanied by a transient increase in free Noxa, a proapoptotic factor. Mcl-1 down-regulation occurs independently of the presence or up-regulation of p53 and of the MYCN status. Taken together, these results suggest that the clinical drug roscovitine and its novel analog CR8 induce apoptotic tumor cell death by down-regulating Mcl-1, a key survival factor expressed in all NB cell lines. CDK inhibition may thus constitute a new approach to treat refractory high-risk NB.
authors.affiliation: C.N.R.S. USR3151, 'Protein Phosphorylation & Human Disease' Group, Station Biologique, Bretagne, France.
authors.forename: Karima
authors.initials: K
authors.lastname: Bettayeb
authors.forename: Dianne
authors.initials: D
authors.lastname: Baunbæk
authors.forename: Claire
authors.initials: C
authors.lastname: Delehouze
authors.forename: Nadège
authors.initials: N
authors.lastname: Loaëc
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Hole
authors.forename: Sonja
authors.initials: S
authors.lastname: Baumli
authors.forename: Jane A
authors.initials: JA
authors.lastname: Endicott
authors.forename: Setha
authors.initials: S
authors.lastname: Douc-Rasy
authors.forename: Jean
authors.initials: J
authors.lastname: Bénard
authors.forename: Nassima
authors.initials: N
authors.lastname: Oumata
authors.forename: Hervé
authors.initials: H
authors.lastname: Galons
authors.forename: Laurent
authors.initials: L
authors.lastname: Meijer